In the past two to three decades, many catalytic antibodies hydrolyzing VIP,
DNA, RNA, HIVgp41, HIVgp120, Factor VIII, H. pylori urease, hemagglutinin of
influenza virus, and amyloid-β have been reported. In recent years, catalytic antibodies
are used in the stages of in vitro testing as well as in vivo against influenza, rabies, and
AIDS viruses. These recent developments are introduced in this chapter.
Currently, antibody drugs have been developed in many countries and companies
throughout the world. It is said, this development is in a “frenzy of scientific
competition,” which may continue for about the next ten years. Alternatively, catalytic
antibodies are far superior to normal antibody drugs, since the former can recognize
and catalytically degrade the antigen. A general technology for the development of
catalytic antibodies is in the pipeline, and once the technology is developed, it could
impact the drug industry as far as the use of catalytic antibodies is concerned. The
general trends in developing the antibodies and other parameters that could influence
the developmental process are discussed here.
Based on these considerations and facts, we will briefly mention the perspectives and
world trends in catalytic antibody research.
Keywords: Acute toxicity, ADCC, Alzheimer, Catalytic antibody, CDC,
Conserved sequence, DNase activity, Germ line gene, Hemagglutinin molecule,
HIV, Human light chain, Infection, Influenza virus, Kinetics, MDCK cells, Rabies
virus, Structural diversity, Suppression, Peptidase activity.
